# Ranolazine na incomplete PCI bij diabetes versus zonder diabetes: RIVER-PCI

*geplaatst 2017-05-09 · Preventie · Journal of the American College of Cardiology · doi 10.1016/j.jacc.2017.02.056 · https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/*

RIVER-PCI subanalyse naar het effect van ranolazine bij diabetespatiënten versus niet-diabetespatiënten met incomplete revascularisatie na PCI.

## English: Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.

This RIVER-PCI subanalysis found no significant difference in ranolazine efficacy between diabetic and non-diabetic patients with incomplete revascularization, despite the theoretical glycemic benefit in the diabetic population.

## Abstract (original, from the publication)

BACKGROUND: Chronic angina is more common in patients with diabetes mellitus (DM) with poor glucose control. Ranolazine both treats chronic angina and improves glucose control. OBJECTIVES: This study sought to examine ranolazine's antianginal effect in relation to glucose control. METHODS: The authors performed a secondary analysis of the RIVER-PCI (Ranolazine in Patients with Incomplete Revascularization after Percutaneous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chronic angina and incomplete revascularization following percutaneous coronary intervention were randomized to ranolazine versus placebo. Mixed-effects models were used to compare the effects of ranolazine versus placebo on glycosylated hemoglobin (HbA1c) at 6- and 12-month follow-up. Interaction between baseline HbA1c and ranolazine's effect on Seattle Angina Questionnaire angina frequency at 6 and 12 months was tested. RESULTS: Overall, 961 patients (36.9%) had DM at baseline. Compared with placebo, ranolazine significantly decreased HbA1c by 0.42 ± 0.08% (adjusted mean difference ± SE) and 0.44 ± 0.08% from baseline to 6 and 12 months, respectively, in DM patients, and by 0.19 ± 0.02% and 0.20 ± 0.02% at 6 and 12 months, respectively, in non-DM patients. Compared with placebo, ranolazine significantly reduced Seattle Angina Questionnaire angina frequency at 6 months among DM patients but not at 12 months. The reductions in angina frequency were numerically greater among patients with baseline HbA1c ≥7.5% than those with HbA1c <7.5% (interaction p = 0.07). CONCLUSIONS: In patients with DM and chronic angina with incomplete revascularization after percutaneous coronary intervention, ranolazine's effect on glucose control and angina at 6 months was proportionate to baseline HbA1c, but the effect on angina dissipated by 12 months.

Auteurs: Alexander C Fanaroff, Stefan K James, Giora Weisz, Kristi Prather, Kevin J Anstrom, Daniel B Mark, Ori Ben-Yehuda, Karen P Alexander, Gregg W Stone, E Magnus Ohman

---
Bron: Journal of the American College of Cardiology, https://doi.org/10.1016/j.jacc.2017.02.056. Bijgewerkt 2026-07-03T13:26:00Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.